The portopulmonary hypertension: an overview from diagnosis to treatment

Submitted: November 25, 2015
Accepted: November 25, 2015
Published: November 25, 2015
Abstract Views: 1389
PDF: 688
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.


Portopulmonary hypertension (POPH) refers to the condition of pulmonary arterial hypertension (PAH) in association with portal hypertension. Among patients with portal hypertension, reported incidence rates of POPH range from 2 to 10% and long-term prognosis in cases of- POPH is poor. Fundamental issues of management of POPH include identification of patients likely to benefit from liver transplantation (LTx) and treatment with specific pulmonary vasodilators before and after LTx. This review presents as an overview of the current knowledge on the epidemiology, diagnosis, treatment and prognosis of patients with portopulmonary hypertension.



PlumX Metrics


Download data is not yet available.


How to Cite

Salzano, Andrea, Domenico Sirico, Luisa Golia, Valentina Faga, Martina Flora, Eduardo Bossone, and Antonio Cittadini. 2015. “The Portopulmonary Hypertension: An Overview from Diagnosis to Treatment”. Monaldi Archives for Chest Disease 80 (2).